Business
Geron Announces Appointment of New Executive to Focus on Corporate Strategy
MENLO PARK, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN) today announced the appointment of Anil Kapur as Executive Vice President, Corporate
About this update from Geron Corporation
[{"type":"text","content":" MENLO PARK, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN) today announced the appointment of Anil Kapur as Executive Vice President, Corporate Strategy and Chief Commercial Officer. With this appointment, all functions of a fully-integrated, late-stage drug development executive leadership team are now in place.\n\n\n“We are pleased to welcome Anil whose proven track record in shaping hematology-oncology development programs, launching blockbuster oncology products and managing external alliances rounds out our executive team’s capabilities,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer. “More importantly, he will provide a commercial lens to Geron’s corporate strategy that will be instrumental as we evaluate current and future indications of imetelstat to maximize the value of the program, as well as other potential assets to diversify the Company’s pipeline over the long-term.”\n\n\nIn his role at Geron, Mr. Kapur will be a member of the Company’s Executive Management Committee. His initial focus will be on developing value-creating strategic plans to build Geron’s hematology-oncology franchise while leading the Company’s assessment of additional indications for imetelstat. As Geron continues to advance the imetelstat program toward potential commercialization over time, he will be responsible for implementing Geron’s commercial strategy and forming a commercial organization.\n\n\n“I am excited to be joining Geron,” said Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer. “Having seen imetelstat’s transformative potential for disease modification through telomerase inhibition while at Janssen, I strongly believe that imetelstat has great promise in hematology-oncology, and look forward to helping strategically build imetelstat and Geron into an important and meaningful enterprise for clinicians, patients, shareholders and employees.”\n\n\nMr. Kapur brings more than 19 years of U.S. and global biopharmaceutical experience to Geron. Most recently, he was Chief Commercial Officer at Actinium Pharmaceuticals, Inc., where he created a strategic commercialization roadmap to help the company transition from clinical stage to a commercial entity. Prior to that, Mr. Kapur was Vice President, Head of Early Assets, Biomarkers and External Innovation for Worldwide Onco...